CURRENT STATUS OF ARTERIAL HYPERTENSION CASE MANAGEMENT This paper presents key provisions of the European Society of Hypertension and European Society of Cardiology guidelines on treatment of arterial hypertension (AH). In particular, the author touched upon issues pertaining to blood pressure (BP) measurements and emphasized the importance of office blood pressure measurement, home-based BP monitoring, and 24-hour BP monitoring. Thus, office BP measurement is still a “golden standard” in AH screening, diagnostics and treatment, while home-based BP measurement allows to detect a so-called “white coat hypertension”, which occurs when BP readings are higher at the doctor’s office than they are in home settings, or masked AH, when BP readings are normal in the office, but elevated in home settings. In addition, patients admitted to specialized health facilities should be recommended 24-hour BP monitoring to enable the detection of a nocturnal BP dipping or elevated blood pressure at night time, which allows for identification of patients with high risk of cardiovascular complications. It is important to take into account new cardiovascular risk markers such as atherosclerotic plaques in carotid artery, rigidity index, renal function assessment, and others for better risk stratification of AH patients. During treatment of AH patients with high risk factors, it is important to prefer combined use of ACE inhibitors, renin angiotensin receptor blockers, dihydropyridine calcium antagonists and thiazide diuretics such as ACE inhibitor and calcium antagonist (Equator 5 mg + 10 mg, 5 mg + 20 mg, 10 mg + 20 mg), ACE inhibitor and thiazide diuretic (Co-Diroton 10 mg + 12.5 mg, 20 mg + 12.5 mg), ARB and thiazide diuretic or calcium antagonist (Co-Sentor  50 + 12.5, 100 + 12.5). Head of Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, (Prague, Czech Republic) Professor R. Cifkova.